Immutep at Bell Potter Healthcare Conference: reset after trial setback
Immutep (IMMP) attended the Bell Potter Healthcare Conference to present its recovery plan following a challenging year that included the termination of a Phase III lung cancer study after a futility analysis of eftilagimod, also known as efti. The company's management believes that its future lies in its diversified pipeline, a rebooted manufacturing process, and a stronger cash position.
Chief Executive Marc Voigt confirmed that Immutep has moved away from a single-asset approach and now has two primary clinical focuses: efti in the realm of oncology and IMP761 in autoimmune diseases. The CEO also noted that the company holds approximately AUD 50 million in cash at the end of the last quarter, which should provide sufficient funding to reach crucial milestones by 2027.
The company's turnaround strategy involves a dual-asset approach, with efti being targeted at selected oncology settings and IMP761 advancing as a novel autoimmune drug candidate. Immutep is actively seeking partnerships and intends to allocate capital carefully, with decisions based on available resources, regulatory feedback, and potential partner support.
The company's market capitalization has decreased to $24.6 million due to a difficult year marked by a 94% year-to-date decline in its share price. However, InvestingPro analysis suggests that Immutep's stock may be undervalued at its current price. The company's balance sheet shows more cash than debt, supporting management's claim of financial stability.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.